Endocrine therapy for prostate cancer

Endocrinol Metab Clin North Am. 1991 Dec;20(4):845-72.


Prostate cancer is the most frequent cancer in men. A discovery of major importance in the endocrinology of prostate cancer is that the testes contribute only 60% of total androgens in adult men; the remaining 40% are synthesized in peripheral tissues, including the normal and cancerous prostate, from inactive androgen precursors of adrenal origin. Using a combination therapy that includes a pure blocker of the androgen receptor or antiandrogen and castration (medical with luteinizing hormone-releasing hormone agonist or surgical by orchiectomy), the duration of response and survival have been demonstrated to be prolonged for the first time in advanced prostate cancer.

Publication types

  • Review

MeSH terms

  • Androgen Antagonists / therapeutic use*
  • Androgen Receptor Antagonists*
  • Androgens / biosynthesis
  • Androgens / genetics
  • Combined Modality Therapy
  • Gonadotropin-Releasing Hormone / analogs & derivatives
  • Gonadotropin-Releasing Hormone / therapeutic use
  • Humans
  • Male
  • Orchiectomy
  • Prostatic Neoplasms / diagnosis
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / surgery


  • Androgen Antagonists
  • Androgen Receptor Antagonists
  • Androgens
  • Gonadotropin-Releasing Hormone